Structure-Based Design of a Benzodiazepine Scaffold Yields a Potent Allosteric Inhibitor of Hepatitis C NS5B RNA Polymerase
摘要:
HCV NS5B polymerase, an essential and virus-specific enzyme, is an important target for drug discovery. Using structure-based design, we optimized a 1,5-benzodiazepine NS5B polymerase inhibitor chemotype into a new sulfone-containing scaffold. The design yielded potent inhibitor (S)-4c (K(D) = 0.79 nM), which has approximately 20-fold greater affinity for NS5B than its carbonyl analogue (R)-2c.
The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I):
wherein R
1
, R
2
, R
3
, R
4
, and m are as defined herein.
The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, rhinitis, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
[EN] ANDROGEN RECEPTOR LIGANDS<br/>[FR] LIGANDS DU RÉCEPTEUR DES ANDROGÈNES
申请人:UNIV DUKE
公开号:WO2017059401A3
公开(公告)日:2018-01-25
US8071584B2
申请人:——
公开号:US8071584B2
公开(公告)日:2011-12-06
[EN] 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTENES USEFUL AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] 1,1-DIOXO-1-THIA-5,10-DIAZADIBENZOCYCLOHEPTÈNES UTILES COMME INHIBITEURS DU VIRUS DE L'HÉPATITE C
申请人:TIBOTEC PHARM LTD
公开号:WO2008099020A1
公开(公告)日:2008-08-21
[EN] Inhibitors of HCV replication of formula (I) the stereoisomers, prodrugs, tautomers, racemics, salts, hydrates or solvates thereof wherein R1a; R1b R2; R3; R4a and R4b have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy. [FR] L'invention porte sur des inhibiteurs de réplication du VHC de formule (I), sur les stéréoisomères, les promédicaments, les tautomères, les racémiques, les sels, les hydrates ou les solvates de ceux-ci. Dans la formule, R1a; R1b ; R2; R3; R4a et R4b ont la signification définie dans les revendications. La présente invention porte également sur des procédés de préparation desdits composés, sur des compositions pharmaceutiques les contenant et sur leur utilisation dans la thérapie du VHC.